Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDK4 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Parenteral
01
Overview
CDK4 siRNA refers to a class of RNA interference-based therapeutics designed to silence the expression of cyclin-dependent kinase 4 (CDK4). CDK4 is a key regulator of the G1 to S phase transition in the cell cycle, and its overexpression is associated with various malignancies, including breast cancer, ovarian cancer, and non-small-cell lung carcinoma (NSCLC). By utilizing small interfering RNAs (siRNAs) delivered via various platforms such as lipid nanoparticles (LNPs), micellar nanoparticles (MNPs), or peptide-based systems, these agents induce the degradation of CDK4 mRNA, leading to cell cycle arrest and apoptosis in tumor cells. Research has also explored its use in synthetic lethal strategies, particularly in KRAS-mutant cancers, and in combination with other therapies like let-7 miRNA or CDK4 inhibitors like palbociclib.
- Other names
- siCDK4siCDK-4siCDK 4CDK4 small interfering RNACDK-4 small interfering RNACDK 4 small interfering RNAcdk4 siRNAcdk-4 siRNAcdk 4 siRNA
02
Targets
CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on CDK4 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDK4 siRNA.